Clinical Trials

Inclusion Criteria

• Newly diagnosed, clinically localized prostatic adenocarcinoma
• Age 50 - 60 years
• Male gender
• Normal preoperative sexual function
• Normal urinary continence
• Regular sexual partner

Exclusion Criteria

• Unable or unwilling to provide informed consent
• Vulnerable study population
• Active systemic infection
• Diabetes mellitus diagnosis
• Preexisting Erectile Dysfunction or urinary incontinence
• Metastatic or locally advanced prostatic adenocarcinoma on preoperative evaluation
• Men found grossly or pathologically to have locally advanced or metastatic disease at the time of radical prostatectomy
• An estimated blood loss of > 750 mL at the time of radical prostatectomy
• Treatment prior to surgery with any form of hormones, anti-androgens or androgen deprivation therapy
• Use of an antidepressant, beta blocker or erectile dysfunction medication at the time of study screening
• Men without a regular sexual partner
• Use of aspirin or heparin 2 weeks before radical prostatectomy
• Need for use of aspirin or heparin for 2 weeks or more after radical prostatectomy